• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    West to Present on Large Volume Delivery Systems, Administration and Transfer Devices, and Prefillable Syringe Component Expertise at the PDA Conference

    10/22/24 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email

    EXTON, Pa., Oct. 22, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2024 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Phoenix, AZ to showcase its leadership and expertise on industry challenges and trends in packaging and containment. 

    (PRNewsfoto/West Pharmaceutical Services, I)

    "With the rise of biologic drugs, injectables are the fastest growing drug segment today, bringing with it new challenges of complex molecules and treatment requirements," says Atul Patel, Vice President, Delivery Devices at West. "As the market leader, West continues to adapt and expand the performance of high-quality drug delivery packaging and devices to meet the changing needs of patients, regulators, and industry partners."

    At this year's PDA, West will be sharing insights through various posters and a presentation on how leveraging primary container and device platforms can reduce risk and accelerate time-to-market for combination products.

    Featured Speaking Session:  

    Title: Enabling High-Volume Drug Delivery with a Platform Approach

    Speaker: Gurmeet Singh, Senior Director, Business Development

    Date and Time: October 22, 2024, 10:25- 10:35am PST

    Featured Posters:  

    Title: Performance of Pre-Filled Syringe Systems at Low Temperature

    Author: Page McAndrew, Director, Scientific Communications

    Title: Container Closure Integrity Testing Strategy for Drug-led Combination Products: A Practical Approach

    Author: Jen Roark, Technology Manager, Scientific Affairs

    Title: Evaluating Vial Adapter Transfer Devices for Reconstitution with Pre-Filled Syringes: Using USP (United States Pharmacopoeia) (TYO:382)

    Author: Ronan Jenkinson, Manager, Sales Business and Development, Combination Product and Services

    Title: Visual Impairment Affordances Can Benefit All Users

    Author: Lisa Lacouette-Ward, Senior Specialist, Regulatory Affairs

    For more information about the PDA Universe of Pre-Filled Syringes and Injection Devices Conference, please visit:  PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2024 | PDA

    About West

    West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year.   

    Headquartered in Exton, Pennsylvania, West in its fiscal year 2023 generated $2.95 billion in net sales. West is traded on the New York Stock Exchange (NYSE:WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.      

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/west-to-present-on-large-volume-delivery-systems-administration-and-transfer-devices-and-prefillable-syringe-component-expertise-at-the-pda-conference-302282228.html

    SOURCE West Pharmaceutical Services, Inc.

    Get the next $WST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What event is West Pharmaceutical Services participating in and why?

      West Pharmaceutical Services is participating in the 2024 PDA Universe of Pre-Filled Syringes and Injection Devices Conference to showcase its expertise in overcoming industry challenges regarding drug packaging and delivery.

    • What are the key presentations or sessions that West will be featuring at the conference?

      The conference will feature various presentations from West, including a session on enabling high-volume drug delivery and multiple poster presentations addressing different aspects of drug delivery systems.

    • What challenges does West identify in the current market for injectable drugs?

      Atul Patel, Vice President of Delivery Devices at West, noted that the rise of biologic drugs presents new challenges, leading to increased complexities in drug delivery.

    • What was West Pharmaceutical Services' net sales in fiscal year 2023 and its market significance?

      West generated $2.95 billion in net sales in fiscal year 2023 and is included in the S&P 500 index, indicating a strong standing in the financial market.

    • Who is presenting at the conference and what is the title and timing of the featured session?

      The featured speaking session titled 'Enabling High-Volume Drug Delivery with a Platform Approach' will be delivered by Gurmeet Singh on October 22, 2024, from 10:25 to 10:35 am PST.

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    12/2/2025$285.00Equal-Weight
    Morgan Stanley
    9/15/2025$311.00Buy
    Rothschild & Co Redburn
    6/24/2025$245.00Equal Weight
    Barclays
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    More analyst ratings

    $WST
    SEC Filings

    View All

    West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    2/12/26 7:21:40 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.

    SCHEDULE 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    10/31/25 11:41:37 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by West Pharmaceutical Services Inc.

    10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    10/23/25 4:14:52 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on West Pharm with a new price target

    Morgan Stanley initiated coverage of West Pharm with a rating of Equal-Weight and set a new price target of $285.00

    12/2/25 8:36:52 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Rothschild & Co Redburn initiated coverage on West Pharm with a new price target

    Rothschild & Co Redburn initiated coverage of West Pharm with a rating of Buy and set a new price target of $311.00

    9/15/25 8:12:22 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on West Pharm with a new price target

    Barclays initiated coverage of West Pharm with a rating of Equal Weight and set a new price target of $245.00

    6/24/25 8:11:45 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    West Reports Fourth-Quarter and Full-Year 2025 Results

    – Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period) Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per sha

    2/12/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack

    Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced participation at Pharmapack 2026 in Paris, France to showcase its leadership and expertise on industry challenges and trends in packaging and containment. This event marks the global commercial availability of West Synchrony™ S1 prefillable syringe (PFS) system. West Synchrony S1 PFS system provides a broad product po

    1/20/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SVP & Chief Financial Officer Mcmahon Robert W. converted options into 4,231 shares and covered exercise/tax liability with 1,250 shares (SEC Form 4)

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    2/12/26 9:37:44 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Haugen Janet Brutschea

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    1/5/26 12:37:29 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by SVP, GC & Corporate Secretary Finch Norman D. Jr.

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    12/10/25 10:33:41 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Financials

    Live finance-specific insights

    View All

    West Reports Fourth-Quarter and Full-Year 2025 Results

    – Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period) Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per sha

    2/12/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Declares Quarterly Dividend

    EXTON, Pa., Dec. 10, 2025 /PRNewswire/ -- On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on February 4, 2026, to shareholders of record on January 28, 2026. About WestWest Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug devel

    12/10/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Leadership Updates

    Live Leadership Updates

    View All

    West Welcomes Robert McMahon as Incoming Chief Financial Officer

    EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.   "Bob is an accomplished CFO and business executive within the

    7/21/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    West Announces Executive Leadership Appointments

    EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

    5/12/22 4:30:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/13/24 5:17:38 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/14/23 12:37:59 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/10/22 8:47:14 AM ET
    $WST
    Medical/Dental Instruments
    Health Care